- Home
- CARM vs BRTX Comparison
CARM vs BRTX Comparison
Compare CARM & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- BRTX
- Stock Information
- Founded
- CARM 2016
- BRTX 1997
- Country
- CARM United States
- BRTX United States
- Employees
- CARM N/A
- BRTX N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- BRTX Managed Health Care
- Sector
- CARM Health Care
- BRTX Health Care
- Exchange
- CARM Nasdaq
- BRTX Nasdaq
- Market Cap
- CARM 12.2M
- BRTX 12.5M
- IPO Year
- CARM N/A
- BRTX N/A
- Fundamental
- Price
- CARM $0.34
- BRTX $1.46
- Analyst Decision
- CARM Hold
- BRTX
- Analyst Count
- CARM 5
- BRTX 0
- Target Price
- CARM $0.90
- BRTX N/A
- AVG Volume (30 Days)
- CARM 25.7M
- BRTX 101.9K
- Earning Date
- CARM 11-06-2025
- BRTX 11-11-2025
- Dividend Yield
- CARM N/A
- BRTX N/A
- EPS Growth
- CARM N/A
- BRTX N/A
- EPS
- CARM N/A
- BRTX N/A
- Revenue
- CARM $10,767,000.00
- BRTX $605,200.00
- Revenue This Year
- CARM N/A
- BRTX $232.67
- Revenue Next Year
- CARM N/A
- BRTX $52.92
- P/E Ratio
- CARM N/A
- BRTX N/A
- Revenue Growth
- CARM N/A
- BRTX 247.62
- 52 Week Low
- CARM $0.14
- BRTX $1.21
- 52 Week High
- CARM $1.27
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- CARM 50.22
- BRTX 51.38
- Support Level
- CARM $0.34
- BRTX $1.56
- Resistance Level
- CARM $0.39
- BRTX $1.63
- Average True Range (ATR)
- CARM 0.06
- BRTX 0.09
- MACD
- CARM 0.00
- BRTX -0.10
- Stochastic Oscillator
- CARM 35.74
- BRTX 77.25
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.